AEON Biopharma, Inc. AEON
0.21 USD 0.00 (-1.70%)
At closeNov 5, 2026, 7:22 AM EST
0.21 0.00 +1.20%
Pre-market · Nov 5, 7:22 AM ET
0.2086 Day range 0.2267
0.177 52-week range 1.45
- YTD
- -81.04%
- 1 year
- -79.35%
- Market cap
- 14.92M
- EPS (ttm)
- -4.39
- Shares out
- 39.97M
- Forward P/E
- -0.84
- YTD return
- -81.04%
- 1-year return
- -79.35%
- Volume
- 6.49M
- Avg volume
- 7.65M
- Open
- 0.2159
- Previous close
- 0.2122
- Day's range
- 0.2086 – 0.2267
- 52-week range
- 0.177 – 1.45
- Beta
- 0.40
- Price target
- 5.00 (+2296.9%)
- Earnings date
- Aug 12, 2024
2Y -62.9310 (-99.67%)
Key statistics
- Enterprise value
- 32.96M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -24.60M
- Total cash
- 3.44M
- Total debt
- 14.69M
- Return on equity
- 0.00%
- Short % of float
- 0.72%
- 50-day average
- 0.76512
- 200-day average
- 2.58
Analyst view
Price target (mean) 5.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate -0.18.
Financials — quick view
AEON Revenue — quarterly 0
AEON Net income — quarterly -1.16M
AEON EPS — quarterly -0.02
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.16 | -0.16 | 0.00 | 0.00% |
| Aug 12, 2024 | Jun 1, 2024 | -0.19 | — | — | — |
| Aug 12, 2024 | Jun 1, 2024 | -0.19 | -0.16 | +0.03 | +15.79% |
| May 14, 2024 | Mar 1, 2024 | -0.31 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.31 | -0.28 | +0.03 | +9.68% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 14, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 10, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 30, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 15, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| May 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About AEON Biopharma, Inc.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- aeonbiopharma.com
News
12 Health Care Stocks Moving In Friday's After-Market Session 
Apple To $355? Here Are 10 Top Analyst Forecasts For Thursday 
Lake Street Maintains Buy on AEON Biopharma, Raises Price Target to $2 - 12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session - 12 Health Care Stocks Moving In Friday's Intraday Session
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
Why AeroVironment Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Your note
Sign in to keep a note on AEON — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARTER ERIC G | Director | Stock Award(Grant) | Aug 29, 2024 | 36,021 |
| FISCHER JOST | Director | Stock Award(Grant) | Aug 29, 2024 | 96,785 |
| FORTH MARC | Chief Executive Officer | Stock Award(Grant) | Aug 29, 2024 | 750,547 |
| OH CHAD M.D. | Officer | Stock Award(Grant) | Aug 29, 2024 | 292,545 |
| PALMISANO ROBERT J | Director | Stock Award(Grant) | Aug 29, 2024 | 36,021 |
| PRIVETERRA SPONSOR, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jul 20, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Polar Asset Management Partners Inc. | 9.01% | 3,599,918 | 2.09M | Sep 29, 2024 |
| Blue Owl Capital Holdings LP | 8.36% | 3,341,204 | 1.94M | Sep 29, 2024 |
| Vanguard Group Inc | 1.88% | 751,343 | 437.21K | Sep 29, 2024 |
| Formidable Asset Management, Llc | 0.98% | 389,782 | 226.81K | Sep 29, 2024 |
| Blackrock Inc. | 0.66% | 265,150 | 154.29K | Sep 29, 2024 |
| Ikarian Capital, LLC | 0.65% | 257,977 | 150.12K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.04% | 414,900 | 241.43K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.80% | 320,899 | 186.73K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.36% | 145,373 | 84.59K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.14% | 54,417 | 31.66K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.12% | 46,260 | 26.92K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 35,140 | 20.45K | Oct 30, 2024 |